VEGFR2报告细胞系/细胞株-ACROBiosystems百普赛斯

VEGFR2 (Luc) HEK293 Reporter Cell

描述（Description）

The Human VEGF R2 (Luc) HEK293 Reporter Cell was engineered to not only express NFAT signaling response element, but also express the receptor full length human VEGF R2 (Gene ID: 3791). When stimulated with human VEGF protein, the VEGF/VEGF R2 interaction drives NFAT-mediated luminescence. Inhibition of VEGF binding to VEGF R2 by either anti-VEGF or anti-VEGF R2 antibodies results in a decrease in luminescence.

应用说明（Application）

1. Screen for anti-human VEGF R2 or anti-human VEGF neutralizing antibody.

2. Screen for human VEGF R2 small molecule inhibitor

生长特性（Growth Properties）

Adherent

筛选标记（Selection Marker）

Hygromycin (50 μg/mL) + Puromycin (5 μg/mL)

培养基（Culture Medium）

DMEM medium + 10% FBS

冻存液（Freeze Medium）

Serum-free cell cryopreservation medium

装量（Quantity）

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储（Storage）

Frozen in liquid nitrogen.

支原体检测（Mycoplasma Testing）

Negative

无菌检测（Sterility Testing）

Negative

使用说明（Instructions for Use）

See data sheet for detailed culturing and assay protocol.

背景（Background）

Vascular endothelial growth factor (VEGF) is a potent angiogenic inducer that stimulates the expression of tissue factor (TF), the major cellular initiator of blood coagulation. VEGF could inhibit apoptosis and increase cellular proliferation. As the most abundant splice variant of VEGF-A, VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2, leads to activation of the PI3K/AKT, p38 MAPK, FAK, and paxillin. Due to the angiogenesis ability of VEGF in cancer, interfering VEGF/VEGFR2 interaction has become an attractive method in cancer therapy.

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.